RxDoctor Payments Data

Richard Heuser, MD

Interventional Cardiology · Phoenix, AZNPI 1962493338

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $54,231 of the $68,434 with a category attached, or 79.2%. Boston Scientific accounts for 79.4% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2019 at $59,176 and has fallen 100.0% since, to $18 in 2025. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,434in general payments, 2019–2025

Across 218 payments — averaging $313.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$54K
  • Siemens Medical Solutions USA, Inc.$4K
  • Penumbra, Inc.$2K
  • Amgen$2K
  • Medtronic$2K
  • Microvention, Inc.$1K
  • plus $4K from 36 others
$43,473in research payments, 2019–2025

Across 17 payments — averaging $2557.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$40K
  • Bard Peripheral Vascular, Inc.$4K

What the payments were for

  • Consulting fees$5,1007%
  • Speaking & faculty fees$1,2502%
  • Travel & lodging$1,5302%
  • Food & beverage$6,3239%
  • Ownership interest$54,23179%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,434 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$72,543
Medicare patients
224
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$37,827
FarxigaDapagliflozin Propanediol11$11,933
NexletolBempedoic Acid14$6,417
Atorvastatin Calcium118$1,067
ClopidogrelClopidogrel Bisulfate95$1,064
Ezetimibe39$910
Metoprolol Succinate44$629
Chlorthalidone37$577
Amlodipine Besylate59$402
Carvedilol34$383
Lisinopril50$333
Losartan Potassium25$327
Metoprolol Tartrate28$278
Rosuvastatin Calcium29$266
Simvastatin13$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$37,82726 claims
AstraZenecaFarxiga$61$11,93311 claims
Esperion Therapeutics, Inc.Nexletol$29$6,41714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →